Kabra Drugs Ltd

NSE: KABRADG · BSE: 524322 · Pharmaceuticals & Biotechnology · 32 announcements

Share price: ₹18.15
Market cap: ₹43.03 Cr
Revenue (annual): ₹92.74 Cr
Net profit (annual): ₹4.96 Cr
P/E (TTM): 5.6×Sector 43.8×
FII holding: 0.00%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Announcement type

All Other Announcement 6 Financial Results 5 Board Meeting Date 5 Annual General Meeting 5 Board Meeting Outcome 3 Management Change 2 Capacity Expansion 2 Results Update 1 Legal & Regulatory 1 Capital Structure Change 1 Annual Report 1

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

32 announcements with these filters

7 Apr 2026 16:03 IST BSE

Other Announcement

Kabra Drugs Other Announcement

Kabra Drugs Limited has submitted its quarterly compliance certificate for the period ended March 31, 2026, as per SEBI regulations. The Registrar and Share Transfer Agent, Skyline Financial Services, confirmed that physical share certificates received for dematerialization were duly verified, mutilated, and cancelled within 15 days.

Open announcement → Read the filing ↗

3 Apr 2026 17:42 IST BSE

Financial Results

Kabra Drugs Q3 FY26 Results: Turns Profitable, Net Profit ₹2.6 Cr

Kabra Drugs Ltd reported net profit of ₹2.6 Cr for Q3 FY26.

Key figure: Net profit ₹2.6 Cr

Open full results → Read the filing ↗